Real-Time Nanoscale Proteomic Analysis of the Novel Multi-Kinase Pathway Inhibitor Rigosertib to Measure the Response to Treatment of Cancer

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1517/13543784.2013.829453
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Quantitative- And Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension

OMICS A Journal of Integrative Biology
GeneticsMolecular BiologyBiochemistryMolecular MedicineMedicineBiotechnology
2012English

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers

PLoS ONE
Multidisciplinary
2015English

Transcriptomic and Functional Pathway Analysis of Human Cervical Carcinoma Cancer Cells Response to Microtubule Inhibitor

Journal of Cancer
Oncology
2015English

A Novel Combination Therapy Approach for the Treatment of Acute Myeloid Leukemia: The Multi-Kinase Inhibitor Sorafenib and the HDM2 Inhibitor Nutlin-3

Haematologica
Hematology
2012English

Mathematical Modelling of the MAP Kinase Pathway Using Proteomic Datasets

PLoS ONE
Multidisciplinary
2012English

Proteomic Analysis Implicates Dominant Alterations of RNA Metabolism and the Proteasome Pathway in the Cellular Response to Carbon-Ion Irradiation

PLoS ONE
Multidisciplinary
2016English

Proteomic Analysis of Plasmodium Falciparum Response to Isocryptolepine Derivative

PLoS ONE
Multidisciplinary
2019English

Stimulatory Effects of the Multi-Kinase Inhibitor Sorafenib on Human Bladder Cancer Cells

British Journal of Pharmacology
Pharmacology
2010English

Proteomic Profiling of Exosomes Leads to the Identification of Novel Biomarkers for Prostate Cancer

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy